Peninsula vaccine maker targets $100M IPO — but not for Covid

With the chief advisor for the Trump Administration's Covid-19 vaccine team as its chairman, vaccine developer Vaxcyte Inc. laid out plans for a $100 million initial public offering. But instead of targeting the coronavirus that has infected more than 5.5 million people worldwide and caused the disease that has killed nearly 350,000, Foster City-based Vaxcyte says it is instead focused on a vaccine against pneumonia. Vaxcyte, a seven-year-old spinoff of South San Francisco's Sutro Bipharma Inc.…